Technology-Based Interventions for Substance Use Treatment Among People Who Identify as African American or Black, Hispanic or Latino, and American Indian or Alaska Native: Scoping Review

Article type: Review Article

Keywords: technology-based interventions, substance use, treatment, health equity, underrepresented, scoping review, mobile phone

License: ©Sarah K Moore, Jesse S Boggis, Phoebe R Gauthier, Chantal A Lambert-Harris, Emily G Hichborn, Kathleen D Bell, Elizabeth C Saunders, LaTrice Montgomery, Eilis I Murphy, Avery M Turner, Nico Agosti, Bethany M McLeman, Lisa A Marsch. Originally published in the Journal of Medical Internet Research (https://www.jmir.org), 03.12.2024. CC BY 4.0 This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in the Journal of Medical Internet Research (ISSN 1438-8871), is properly cited. The complete bibliographic information, a link to the original publication on https://www.jmir.org/, as well as this copyright and license information must be included.

Article links: DOI: 10.2196/53685  |  PubMed: 39626234  |  PMC: PMC11653051

Relevance: Moderate: mentioned 3+ times in text

Introduction

Background

In the United States, underrepresented minority (URM) groups, including African American or Black, Hispanic or Latino, and American Indian or Alaska Native populations, have experienced more barriers to substance use treatment engagement than their White counterparts [ref. 1]. These URM groups comprised only 15% of admissions to publicly funded substance use treatment programs in 2020, whereas White populations comprised 77% of admissions [ref. 2]. While the treatment gap is large for all, these gaps are greater for URM groups [ref. 3]. Among African American or Black and Hispanic or Latino populations diagnosed with a substance use disorder, 93% and 95%, respectively, did not receive treatment in 2021 [ref. 4]. Of the few URM groups who do access treatment, African American or Black and Hispanic or Latino populations are the largest groups and are less likely to complete treatment compared to White individuals [ref. 5–ref. 8].

American Indian or Alaska Native populations are overall at an increased risk of substance use disorder, particularly for alcohol use disorder [ref. 9]. These populations have historically been associated with excessive alcohol consumption, and yet a recent study using national survey data to compare alcohol use between American Indian or Alaska Native and non-Hispanic White individuals found limited differences for race and ethnicity, but the odds of binge drinking in male individuals were over twice those of their female counterparts [ref. 10,ref. 11]. It is notable that the number of American Indian or Alaska Native populations has consistently been too low to assess the treatment gap for those with a substance use disorder [ref. 4]. This statistical problem is likely due to the common research analytic strategy of collapsing demographic data into “more than one race,” thereby losing the potential insights into differences among those in this general category. Awareness of environmental risk factors (eg, for American Indian or Alaska Native populations, related to forced assimilation, such as living in geographically isolated communities without economic opportunities and the cross-generational transmission of the cumulative emotional and psychological trauma of cultural genocide) are essential to both prevention and treatment of substance use for all 3 URM groups that are the focus of this scoping review [ref. 10].

Disparities in treatment outcomes remain for these URM groups due in part to differences in social determinants and systemic racism as risk factors [ref. 1,ref. 12–ref. 14]. These differences are preventable as they are likely largely due to structural disadvantages that result in limited opportunities in health care, education, social context, economic stability, and the environment (ie, social determinants of health). To comprehensively address health equity—a state in which all people have a fair opportunity to attain their full health potential and well-being and no one is disadvantaged from doing so because of social position or any other socially defined circumstance [ref. 15]—avoidable inequalities and historical and contemporary injustices must be addressed to eliminate health care disparities.

Treatment intervention research, including substance use treatment research, has infrequently been conducted with people who identify as belonging to racial, ethnic, or both minority groups [ref. 16]. Indeed, a recent systematic review found that only 9 randomized controlled trials examined differences in substance use treatment outcomes by race or ethnicity for African American or Black and Hispanic or Latino populations, with even fewer reporting on differences in the baseline social determinants of health [ref. 17]. Thus, the state of treatment intervention research—particularly substance use treatment research—is a glaring example of limitations of opportunity for URM groups with respect to health care.

Advances in technology-based interventions (TBIs) show promise in reducing barriers and expanding access to evidence-based treatments [ref. 18]. However, there is a risk that TBIs may further exacerbate inequities by disproportionately benefiting people from higher socioeconomic status (SES) groups, who are largely White individuals [ref. 19]. Apprehension of this risk is warranted; throughout history in the United States, these URM groups have experienced violence and displacement due to settler colonialism (eg, for African American or Black individuals, capture from Africa and forced slavery and the US government’s social construction of Blackness as innately diseased due to presumed biological inferiority [ref. 15]; for Hispanic or Latino individuals, pre- and postmigration factors increasing the risk of intergenerational trauma, precarity due to legal status, discrimination, and anti-immigrant policies [ref. 20]), leading to the unequal distribution of resources and an overall lower SES [ref. 21,ref. 22]. However, in recent years, TBIs are increasingly being culturally adapted with the aim of increasing intervention effectiveness for specific URM groups [ref. 23–ref. 25]. In a systematic review of general technology use by URM groups, Montague and Perchonok [ref. 26] found that, while technology can be used to positively impact these communities, the technology must be culturally tailored to the specific URM group community to create positive behavior change. However, within substance use treatment, there has been limited research as to which specific characteristics of TBIs are most effective for URM groups [ref. 16].

Objectives

This scoping review aimed to answer one primary question: does the use of TBIs in substance use treatment research promote health equity among people who identify as African American or Black, Hispanic or Latino, and American Indian or Alaska Native individuals? We operationally defined health equity as the inclusion of members of underrepresented groups (previously specified) in research on TBIs for substance use, as well as the extent to which the research is race and ethnicity conscious. Thus, the following questions helped establish an effective search strategy and results that responded to the primary research question: does research on TBIs for substance use treatment include people who identify as African American or Black, Hispanic or Latino, or American Indian or Alaska Native individuals? If the substance use research on TBIs does include people who identify as African American or Black, Hispanic or Latino, or American Indian or Alaska Native individuals, is it race and ethnicity conscious?

Methods

Protocol

This scoping review followed the PRISMA-ScR (Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews) [ref. 27]. The PRISMA-ScR checklist can be found in Multimedia Appendix 1. A summary of the methods is provided in this section, with a published protocol publicly available [ref. 28].

Study Eligibility Criteria

Overview

The Joanna Briggs Institute—an organization that offers guidance for conducting systematic scoping reviews—recommends the use of the “PCC mnemonic” (population, concept, and context) for defining the focus of a review. The context for our review was substance use and disorder treatment research; the concept was TBIs; and the population were studies with samples that included at least 50% of participants who identified as African American or Black, Hispanic or Latino, or American Indian or Alaska Native individuals when combined [ref. 29].

Inclusion Criteria

The study inclusion criteria were US-based, English-language, peer-reviewed studies of TBIs for substance use treatment with a sample of at least 50% of participants identifying as African American or Black, Hispanic or Latino, or American Indian or Alaska Native individuals (combined) published between January 2000 and March 2021. The decision for the threshold of 50% was based on a review of evidence-based treatments for youth from ethnic minority groups. After the evidence-based criteria were met, the interventions were considered well established, probably efficacious, or possibly efficacious for youth from ethnic minority groups if supporting studies met one or more of several conditions, including whether at least 75% of participants in the study identified as being from ethnic minority groups [ref. 30]. By choosing a 50% threshold, we were more inclusive and likely netted more studies than we would have if we had chosen a 75% cutoff. We focused on this period due to a rising trend in the number of published studies starting in 2001 involving the design and development of technology-based behavior change interventions [ref. 31]. Study design criteria included qualitative, quantitative, and mixed methods studies.

Exclusion Criteria

We excluded the following manuscript types: protocol papers, descriptions of future work, reviews, commentaries, editorials, opinion pieces, student theses, conference abstracts, book chapters, and guidelines. Tobacco intervention studies were also excluded from this review. (see the work by Hichborn et al [ref. 32] for a separate scoping review on tobacco-focused TBI studies).

Data Sources and Search Strategy

Before enlisting the help of research librarians, study team members conducted preliminary independent literature searches in PubMed and Google Scholar using search terms associated with the 3 domains of interest—TBIs, substance use treatment, and sample inclusion of members of URM groups—to identify whether there was indeed a gap in the literature to be filled by this scoping review. This step netted dozens of research studies that appeared to meet the inclusion criteria, confirming the gap in the literature. Following these exploratory efforts, a comprehensive search strategy was implemented using 5 electronic databases (MEDLINE, Scopus, Cochrane Library, CINAHL, and PsycINFO) to identify research that included substance use and disorder treatment interventions using TBIs [ref. 29]. The literature searches were conducted by 2 Dartmouth College reference librarians in consultation with the research team. The final electronic search strategy for MEDLINE can be found in Multimedia Appendix 2.

Screening and Selection Procedure

Duplicate studies were removed in EndNote X9 (Clarivate Analytics), and the remaining studies were uploaded into the web-based review tool Rayyan (Rayyan Systems Inc) [ref. 33] for screening and selection. Studies were first screened at the title and abstract level and then selected for inclusion after a full-text review by a group of 8 reviewers (SKM, CAL-H, PRG, NA, ECS, EGH, KDB, and AMT) working in 3 small teams. Throughout the independent selection process, individual reviewers were blinded to each other’s decisions. The reviewers met regularly to discuss discrepancies and reach a consensus both within teams and as a full group.

Data Extraction

The review team developed a standardized data extraction form in Microsoft Excel (Microsoft Corp) with predefined variables (Textbox 1). A standard operating procedure provided general extraction guidelines, variable definitions, and expected location of variables within the manuscripts. Before data collection, the reviewers piloted the extraction form with 2 studies and reviewed for reliability across team members. At this stage 2 more team members were added, and a 9-person review team continued to work in 3 small groups, with each team member individually performing extraction for a sample of articles within the pool assigned to their team. All studies had a second team member perform a quality assurance data validation check for accuracy, consistency, and thoroughness in the data extraction fields, mainly focusing on fields with the greater likelihood for inconsistency (eg, TBI).

Data Synthesis and Analysis

Organization

We organized netted studies by programs of research, which were defined as ≥2 studies that involved coauthorship networks and referenced the same TBI. Studies were classified as race or ethnicity conscious (yes or no) if the article specifically described research practices informed by at least one URM group in at least one section of the article (ie, title, introduction, method, results, or discussion; Textbox 2). Tables pertaining to race or ethnicity consciousness were populated with data relevant to the studies’ specific reference to the 3 URM groups across manuscript sections. The remaining extracted data served to represent the range of the studies and the nature of TBIs in their respective tables, as well as access and inclusion variables.

Analysis

Included sources of evidence for scoping reviews are not critically appraised regarding methodological quality or risk of bias, making scoping reviews significantly different from systematic reviews. However, one of the PRISMA-ScR items includes an optional “critical appraisal of individual data sources” [ref. 27]. In this study, we aimed to critically appraise the research in terms of each study’s potential to help us better understand the impact of a TBI for members of URM groups. Our rationale for the critical appraisal was founded on the notion that promoting health equity includes highlighting all netted research and not solely focusing on the TBIs that have been found to be effective. To conduct the critical appraisal, we organized the studies by levels of inclusion of a single URM and race or ethnicity consciousness. A higher appraisal or confidence was assigned to studies explicit in presenting results clarifying study implications with samples that included ≥90% of members of a single URM group or included race-conscious results such that the findings were interpretable due to subgroup analyses based on race or ethnicity (eg, 30% African American or Black participants). A lower appraisal or confidence was assigned to those studies that included <90% of members of a single URM group and lacked race-conscious results.

The greater the representation of a single URM group in a sample, the more likely the findings were to have direct implications for that group regardless of whether the results were race conscious.

Results

Sources of Evidence

The systematic searches identified 6897 references (Figure 1 [ref. 27]). Title and abstract screening excluded 83.21% (5739/6897) of the references, and a further 90.5% (1048/1158) of the papers were excluded at full-text review, resulting in 110 studies meeting the inclusion criteria for this scoping review. Full-text review excluded 50.67% (531/1048) of the studies due to ineligibility based on demographic criteria or the absence of race or ethnicity data. Most of the studies (81/110, 73.6%) were published from 2014 onward.

Scoping Review Dataset

The dataset was organized by programs of research (76/110, 69.1% of the studies) and independent studies, defined as studies without companion publications in the dataset (34/110, 30.9%; Table 1).

Study Characteristics

Study designs included 39.1% (43/110) randomized trials, 36.4% (40/110) feasibility studies, 7.3% (8/110) development studies, 6.4% (7/110) secondary analyses, 5.5% (6/110) assessments (ie, interactive voice response, ecological momentary assessment [EMA] solely, with TBI development planned), and 5.5% (6/110) miscellaneous study types. Of the eligible studies, 31.8% (35/110) examined TBIs combined with or integrated into treatment as usual (TAU), whereas 24.5% (27/110) examined TBIs combined with treatment or treatments that were novel to the existing treatment program (eg, motivational interviewing, contingency management [CM], and supportive messages). Of the 27 studies examining TBIs combined with novel treatments, 6 (22%) combined more than one novel treatment with the TBI (eg, naloxone training, HIV, and hepatitis C virus testing; motivational interviewing or transtheoretical model; reading scripture followed by song or relation breathing exercises; or cognitive behavioral therapy [CBT] or tai chi). Of the 110 included studies, 59 (53.6%) reported the use of a comparator to the TBI. Comparators included other TBIs (31/59, 53%); in-person, clinician-delivered versions of the TBI (10/59, 17%) and briefer versions of the targeted TBI (6/59, 10%); TAU (16/59, 27%); nonactive interventions (eg, reading a pamphlet; excluding TAU; 30/59, 51%); motivational interviewing (7/59, 12%); CBT or counseling (4/59, 7%); SMS text messaging or EMA (5/59, 8%); and others (16/59, 27%; eg, DVDs or videos, brochures and website resources, and assessment-only groups).

Beyond the sources of evidence, resultant scoping review dataset and study characteristics typically reported in scoping reviews, the following result subsections (ie, Access or Inclusion, Range and Nature of TBIs, Race and Ethnicity Consciousness, and the critical appraisal of the dataset) all derive from the primary research question and related subquestions developed based on the operationalization of health equity promotion.

Access and Inclusion

Racial or Ethnic Sample Profiles (Analyzed Data)

In 78.2% (86/110) of the included studies, at least 50% of the participants were members of a single URM group: American Indian or Alaska Native (4/86, 5% of the studies) [ref. 34–ref. 37], Hispanic or Latino (15/86, 17% of the studies) [ref. 38–ref. 52], and African American or Black (67/86, 78% of the studies; Tables 2 and 3). While most of the studies on African American or Black individuals also included people who identified as Hispanic or Latino and vice versa, only 12.3% (13/106) of the studies with a majority of African American or Black or Hispanic or Latino individuals included people who identified as American Indian or Alaska Native individuals [ref. 46,ref. 47,ref. 49,ref. 53–ref. 62].

Recruitment and Retention Efforts

A total of 65.5% (72/110) of the included studies recruited participants from medical centers (43/72, 60%), substance use treatment settings (26/72, 36%), or combined and integrated medical and substance use treatment programs in academic settings (3/72, 4%). A handful of studies recruited from social service programs (6/110, 5.5%; eg, Special Supplemental Nutrition Program for Women, Infants, and Children; foster care transition services; and crisis shelters), justice settings (5/110, 4.5%; eg, courts and programs for driving under the influence), and community settings (2/110, 1.8%; eg, church and syringe service programs). A total of 16.4% (18/110) of the studies recruited from more than one setting, and in other studies, recruitment was not described (2/110, 1.8%) or did not apply (4/110, 3.6%; eg, secondary analyses). Retention efforts included compensation for study participation, the device delivering the TBI being given to participants to keep after study completion, and a combination of these strategies. Some studies did not describe retention efforts, and in many instances, they were not applicable (ie, single-session TBI).

Device or Internet Access Requirements

Most studies (64/110, 58.2%) did not require access to the internet or a device for the TBIs. Among the studies that required internet or a device, 24.5% (27/110) provided devices either to all study participants or to those in need, and 18.2% (20/110) required participants to own or have access to a device to be eligible to take part in the study. The TBIs in 39.1% (43/110) of the studies were delivered on-site and required internet access, whereas in 25.5% (28/110) of the studies, they were delivered in remote settings and also required internet access. Geographically, the TBIs in 51.8% (57/110) of the studies were delivered in urban settings; however, 44.5% (49/110) of the studies did not clearly report the geographic setting. A total of 49.1% (54/110) of the studies described the involvement of potential end users, defined as individuals or groups for which the technology was developed, in the formative development or adaptation of a TBI using one or more of the following: interviews (19/54, 35%) [ref. 34,ref. 35,ref. 48,ref. 49,ref. 52, ref. 54,ref. 59,ref. 69,ref. 76,ref. 82,ref. 84,ref. 87,ref. 108,ref. 114,ref. 118,ref. 119,ref. 121,ref. 124,ref. 132], focus groups (15/54, 28%) [ref. 35,ref. 36,ref. 42,ref. 45,ref. 53,ref. 60,ref. 82,ref. 84,ref. 88,ref. 110, ref. 120,ref. 135,ref. 136], feedback sessions or gathering (11/54, 20%) [ref. 60,ref. 61,ref. 63–ref. 65,ref. 67,ref. 68,ref. 70,ref. 75,ref. 128,ref. 130], surveys (13/54, 24%) [ref. 48,ref. 50,ref. 53,ref. 70,ref. 76,ref. 82,ref. 94,ref. 107,ref. 116–ref. 118,ref. 122,ref. 141,ref. 143], usability testing (6/54, 11%) [ref. 47,ref. 54,ref. 58,ref. 108,ref. 110,ref. 112], and review by native speakers of the new adaptation (3/54, 6%) [ref. 40,ref. 41,ref. 115]. Many studies detailed the use of more than one method to involve potential end users.

End-User Groups

The dataset can be categorized into 11 end-user groups: childbearing-aged, pregnant, or perinatal women (22/110, 20%) [ref. 35,ref. 36,ref. 43,ref. 44,ref. 47,ref. 54,ref. 63–ref. 75,ref. 77,ref. 106,ref. 120], people living with HIV or AIDS (18/110, 16.4%) [ref. 39,ref. 61,ref. 83–ref. 87,ref. 112–ref. 115, ref. 118,ref. 122,ref. 124,ref. 131,ref. 135,ref. 136,ref. 139,ref. 141], people in substance use treatment (17/110, 15.5%) [ref. 34,ref. 37,ref. 60,ref. 96–ref. 100,ref. 104,ref. 107,ref. 108, ref. 119,ref. 121,ref. 122,ref. 127], people who inject drugs (2/110, 1.8%) [ref. 52,ref. 125], people seeking substance use treatment (15/110, 13.6%) [ref. 38,ref. 40,ref. 41,ref. 55–ref. 58,ref. 78–ref. 82,ref. 105,ref. 109,ref. 129], adolescents or youth (12/110, 10.9%) [ref. 45,ref. 48,ref. 88–ref. 90,ref. 94,ref. 116,ref. 117,ref. 133,ref. 140], youth exiting foster care (2/110, 1.8%) [ref. 53,ref. 75], people who were justice or court involved (6/110, 5.5%) [ref. 42,ref. 49,ref. 50,ref. 95,ref. 110,ref. 137], people being treated in hospital (detoxification) or emergency departments (6/110, 5.5%) [ref. 46,ref. 91–ref. 93,ref. 134], people who were unhoused (4/110, 3.6%) [ref. 59,ref. 111,ref. 126,ref. 130], men who have sex with men (5/110, 4.5%) [ref. 101–ref. 103,ref. 118,ref. 132], veterans (2/110, 1.8%) [ref. 123,ref. 143], non–treatment-seeking adults (1/110, 0.9%) [ref. 128], community recruits (2/110, 1.8%) [ref. 62,ref. 142], and college students (1/110, 0.9%) [ref. 138].

Social Determinants of Health

When conducting a parallel scoping review that focused on tobacco use [ref. 32], we observed patterns of reported environmental conditions indicative of low SES (eg, being unemployed, having a low or poverty-level income, and being uninsured) among study participants. On the basis of this observation, we explored the dataset for this review and found similar patterns of low income (20/110, 18.2%; eg, 81% of the participants had a barely or totally inadequate income) [ref. 116], unemployment (31/110, 28.2%; eg, “18 subjects and only one was employed”) [ref. 118], lack of health insurance or state insurance (6/110, 5.5%; eg, 86% of the participants were on Medicaid or uninsured) [ref. 108], homelessness (4/110, 3.6%; eg, homeless adult patients in treatment [ref. 126]), or low educational attainment (8/110, 7.3%; eg, average of 12 years of education) [ref. 143]. Another group of studies in this review included those on adolescents that reported no SES (9/110, 8.2%). Notably, many of the people in these samples fit multiple low-SES categories, but the studies were categorized without duplication based on the most salient SES variable in the study demographics (eg, ≥50% of the sample). Finally, 15.5% (17/110) of the studies, which were focused on adults, did not report SES, and another 10.9% (12/110) of the studies appeared to have higher average levels of SES (eg, more than half of the sample were employed). Thus, aside from studies on adolescents and other studies that did not report SES, as well as a small group that had participants of a slightly higher SES, the study samples of the remaining 65% of the studies represented people with a very low SES.

Range and Nature of TBIs

Platform

Almost half (58/110, 52.7%) of the studies used computer-based intervention platforms, including electronic screening, brief interventions, and referrals to treatment. More specifically, 22.7% (25/110) of the studies used electronic screening, brief interventions, and referrals to treatment. Computer-based interventions were delivered via tablets and computers both with and without internet. One-third (37/110, 33.6%) of the dataset represented interactive voice response, EMAs or recovery support EMA interventions, or SMS text messaging intervention platforms delivered both with and without internet via mobile phones. The last large platform category was video, videoconferencing, or telepsychiatry (14/110, 12.7%). The remaining platforms included virtual reality or avatars (2/110, 1.8%) delivered via a computer, a pill dispenser+CM (1/110, 0.9%), a mobile app (1/110, 0.9%), mobile CM (1/110, 0.9%), and an email intervention delivered via a computer (1/110, 0.9%).

Substance Use Categories

Study-labeled substance use categories included alcohol or drug use or alcohol, tobacco, or drug use (45/110, 40.9%); alcohol only (27/110, 24.5%); and drug use only (6/110, 5.5%). Of the 110 studies, there were 8 (7.3%) opioid-focused studies [ref. 107–ref. 109,ref. 121,ref. 122,ref. 125–ref. 127], 5 (4.5%) that focused on opioids and cocaine [ref. 46,ref. 98–ref. 100,ref. 131], and 1 (0.9%) on opioids and tobacco [ref. 139]. A total of 5.5% (6/110) of the studies were cannabis focused [ref. 77,ref. 92,ref. 105,ref. 116,ref. 117,ref. 143], and an additional 4 were cannabis or alcohol focused (n=2, 50%) [ref. 59,ref. 93], cannabis or alcohol or drug use focused (n=1, 25%) [ref. 90], and cannabis or tobacco focused (n=1, 25%) [ref. 142]. Finally, 3.6% (4/110) of the studies focused on cocaine exclusively [ref. 61,ref. 115,ref. 128,ref. 130], and 2.7% (3/110) of the studies focused on methamphetamines [ref. 101–ref. 103]. It is important to note that the use of the study authors’ substance use labels resulted in an overlap of categories (eg, alcohol or drug use overlaps with drug use and cannabis, opioids, cocaine, and methamphetamines; Tables 2 and 3).

Behavior Change Theories and Techniques

One of the extraction variables for the review was behavior change theories and techniques. Of the 110 analyzed studies, 81 (73.6%) were based on at least one underlying behavior change theory, whereas 29 (26.4%) did not report an underlying theory or it was not applicable (ie, EMA studies). The top 6 most frequently referenced underlying theories were CBT (41/81, 51%); (20/81, 25%) screening, brief interventions, and referrals to treatment (10/81, 12%); self-determination theory (5/81, 6%); social cognitive theory (4/81, 5%); and the health belief model (4/81, 5%). A total of 78.2% (86/110) of the studies reported using at least one behavior change technique in their TBIs. Studies reported including the following behavior change techniques: feedback (33/86, 38%), goal setting (19/86, 23%), skill training (18/86, 21%), reminders (17/86, 20%), self-monitoring (16/86, 19%), EMA (14/86, 16%), and social support (7/86, 8%).

Access or Delivery Mode and Frequency

The TBIs were most commonly accessed or delivered independently, with the interventions in 65 studies either being self-initiated (n=45, 69%) or using software-automated prompts (n=20, 31%). A subset of the TBIs were delivered with the support of another individual, including service providers (15/110, 13.6% of the studies) and research team members (7/110, 6.4% of the studies). The interventions in 11.8% (13/110) of the studies were delivered via a hybrid model, combining self-initiated with personnel support. Delivery frequency of the included TBIs was predominantly in a single session (with or without booster sessions; 30/110, 27.3% of the studies) or daily for a limited period (25/110, 22.7% of the studies).

Programs of Research

Programs of research (16/16, 100%) ranged from a minimum of 2 to a maximum of 17 studies and, in some cases, spanned decades. Given space constraints, we feature the 2 largest programs (Motivation Enhancement System [MES] and Computer-Based Training for Cognitive Behavioral Therapy [CBT4CBT]) and encourage readers to explore other programs and independent studies (Tables 2 and 3) to obtain a sense for how a program of research might evolve to promote health equity. The largest program was MES, a computer-delivered, single-session, self-initiated brief intervention originated in a publication in 2005 [ref. 63]. This early study provided the material for an additional 14.5% (16/110) of the studies in the dataset, all of which explored MES’s utility primarily among perinatal or childbearing-aged women who identified as African American or Black individuals. MES was explored for utility among young adults who had recently exited foster care (ie, interactive health lifestyle preparation) and for utility with perinatal or childbearing-aged women who had different substance use profiles. The single-session nature of the tool also evolved to be combined with SMS text messaging within the program of research.

The second largest program (10/110, 9.1% of the studies) was CBT4CBT, a self-initiated, multi-session computer- or tablet-based version of CBT used in conjunction with standard clinical care for people currently using substances. The original, small-efficacy study comparing CBT4CBT to TAU [ref. 55] was referenced as source material in an additional 8.2% (9/110) of the studies in the dataset, including exploration of the TBI in small randomized trials exploring mechanisms as well as a culminating randomized controlled trial evaluating the efficacy and safety of CBT4CBT as a stand-alone treatment. The largest proportion of the samples in the first 70% (7/10) of the studies within this program comprised people who identified as African American or Black; however, each sample also included people who identified as Hispanic or Latino and some who identified as American Indian or Alaska Native. A total of 20% (2/10) of the most recent studies in this program of research included clear examples of work to promote health equity. Paris et al [ref. 38] described the primary outcomes of a randomized trial comparing a culturally adapted version of CBT4CBT (CBT4CBT-Spanish) to standard mental health and addiction treatment in treatment-seeking Latino adults, and Jordan et al [ref. 82] assessed the feasibility outcomes of a clinical trial for African American or Black adults with substance use disorder in a novel setting—a Black church, where modifications to the TBI were made by church-based health advisors.

Race and Ethnicity Consciousness

A total of 26.4% (29/110) of the studies met our race or ethnicity consciousness criteria that at least one manuscript section be explicit about a particular URM group. In total, 24% (7/29) of these studies included samples that comprised 100% members of a single URM group and were race or ethnicity conscious across all manuscript sections—acknowledging a racial or ethnic group in the title, introduction, methods, results, and discussion sections (African American or Black individuals [ref. 82,ref. 120], American Indian or Alaska Native individuals [ref. 34–ref. 36], and Hispanic or Latino individuals [ref. 40,ref. 41]). An additional 17% (5/29) of the studies [ref. 38,ref. 42,ref. 44,ref. 51,ref. 132] were race or ethnicity conscious across all sections except for the manuscript title. Among the remaining 59% (17/29) of the studies, evidence of race or ethnicity consciousness was present yet inconsistent (Table 4).

Critical Appraisal

Higher appraisal or confidence logically comes from studies with race- or ethnicity-conscious results with samples that included ≥90% of members of a single URM group (10/110, 9.1%) [ref. 34,ref. 35,ref. 38,ref. 40–ref. 42,ref. 82,ref. 120,ref. 121,ref. 132]. Despite not having race- or ethnicity-conscious results, the samples of 11.8% (13/110) of the studies included ≥90% of members of a single URM group, making the results intrinsically applicable to that group (ie, functionally equivalent to being race conscious) [ref. 37,ref. 45,ref. 63–ref. 66,ref. 69,ref. 104,ref. 128,ref. 130,ref. 131,ref. 142]. A small group of studies (8/110, 7.3%) [ref. 36,ref. 43,ref. 44,ref. 51,ref. 72,ref. 97,ref. 112,ref. 134] had samples comprising <90% of members of a single URM group; however, due to their race- or ethnicity-conscious results, there was higher confidence in interpretable findings. A lower appraisal or confidence rating was assigned to those studies that included <90% of members of a single URM group and lacked race-conscious results (79/110, 71.8%). As samples increase in racial or ethnic diversity, without subgroup analyses, it becomes challenging to clearly interpret outcomes for different groups. Table 5 shows the critical appraisal of all the studies in the dataset.

Discussion

Health Equity Promotion

Overview

To our knowledge, this scoping review is the first systematic literature exploration of health equity promotion in TBIs for substance use treatment among URM groups at heightened risk of disparities in substance use treatment and related outcomes in the United States [ref. 6,ref. 144–ref. 146]. This review offers insights into the extent to which the evaluated studies promote health equity and identifies opportunities for growth. Productive health equity research focuses on strengths and solutions in lieu of redocumenting problems [ref. 24,ref. 147,ref. 148]. All the identified areas of opportunity for growth will include examples for how to promote equity in these spaces.

Access or Inclusion

An analysis of US trials in ClinicalTrials.gov [ref. 149] revealed that, over the past 2 decades (2000-2020), most registered studies did not report race and ethnicity enrollment data and, among those with demographic data, racial or ethnic minority groups were underrepresented. It is noteworthy that federal requirements to report have only been in place since 2017. In our review, nearly half (532/1158, 45.9%) of the full-text articles assessed for eligibility were excluded due to either ineligibility based on demographic criteria or the absence of reporting of race or ethnicity data, substantiating this historical pattern of lack of access or inclusion that perpetuates health inequity for some of the most vulnerable members of our society. Of those studies that did include URM groups, approximately half (57/110, 51.8%) described engagement of end users in some stage of the TBI research. The scientific community is increasingly focusing on translation and implementation of scientific discoveries with a parallel increase in attention to end-user engagement as a key component in the process of tailoring best practices for specific populations who are hardly reached by research and, thus, disproportionately impacted by chronic health conditions [ref. 150,ref. 151]. The promotion of representation and equity in research are by-products of these foci [ref. 152]. As will be discussed more extensively in the following sections, community-engaged and culturally informed interventions have been demonstrated to improve the health outcomes of underserved groups facing health disparities [ref. 26,ref. 153,ref. 154]. Research collaboration with the communities we seek to serve and partner with to promote health equity through the development of TBIs for substance use is essential.

Range and Nature of TBIs

Most of the netted studies (76/110, 69.1%) were programs of research, highlighting the importance of conducting various types of research studies focused on different stages of science or scientific questions (eg, intervention development, efficacy studies, and effectiveness studies), consistent with the National Institutes of Health (NIH) Stage Model for behavioral intervention development, with the ultimate goal of producing highly potent and maximally implementable interventions that improve health and well-being [ref. 155]. This model is also consistent with the path to understanding the replicability and reproducibility of effects in various contexts and populations [ref. 24]. The independent studies netted by this review are disproportionately more recent publications, pointing to future research programs with commitments to URM group health equity promotion. Although expected given the rapid proliferation in TBIs in health research generally, the increased volume in recent years, as well as the range of substances targeted by the studies in this dataset, are encouraging signs.

The prevalence of independently delivered or accessed TBIs is notable given the potential for many underserved people to live in contexts in which access to care may be limited. In addition, many people who identify as members of URM groups may be reluctant to engage in traditional models of care due to mistrust of the research and medical communities [ref. 156–ref. 158]. Furthermore, the prevalence of brief evidence-based interventions accessed or delivered independently reduces the threshold to receive an effective dose of the intervention [ref. 159]. Efforts to simplify technological complexity are likely to disproportionately benefit less advantaged groups [ref. 19,ref. 160], possibly due to the effort involved in negotiating additional barriers to health behaviors that emerge in underserved contexts [ref. 161].

Race and Ethnicity Consciousness

Abandoning color-blind approaches to research potentiates exploration of treatment impacts that values the perspectives and voices of others [ref. 162]. Approximately one-quarter of the studies (29/110, 26.4%) were explicitly conscious of members of underrepresented racial and ethnic groups in their research. Most of the race- or ethnicity-conscious studies (23/29, 79%) also engaged end users and community members in the design or conduct of the research, further amplifying their voices. These exemplars stand in contradistinction to acontextually developed innovations that may largely benefit health outcomes in one sector of society while potentially creating, sustaining, or increasing health disparities in another [ref. 163].

Critical Appraisal

The trend toward an increased focus on including URM groups in TBI research, as well as the increased race and ethnicity consciousness of this research, is unquestionably a positive finding. However, most studies (79/110, 71.8%) were limited in the extent to which the outcomes could be interpreted to have implications for people who identify as African American or Black, Hispanic or Latino, or American Indian or Alaska Native individuals. In our critical appraisal, 28.2% (31/110) of the studies were highly appraised in terms of the interpretability of findings for one or more URM groups. Through this appraisal of the dataset, as well as the scoping review at large, we hope to encourage researchers to identify existing TBIs for potential adaptation, potential gaps in the knowledge base, or insights for new tool development.

Opportunities for Growth

Careful attention to patterns in the review data illuminate several opportunities for promoting health equity in substance use treatment research with URM groups: lowering access thresholds to increase participation in research, especially among Hispanic or Latino and American Indian or Alaska Native individuals; expanding TBI substance use research focusing on opioids, stimulants, and cannabis; using culturally informed theoretical models or equity approaches to knowledge production; planning and conducting racial and ethnic subgroup analyses; adapting TBIs with demonstrated effectiveness for examination with URM groups; and considering intersectionality.

Lowering Access Thresholds to Increase Participation, Especially Among Hispanic or Latino and American Indian or Alaska Native Individuals

To enhance inclusion, low-threshold, community-based recruitment strategies and settings are needed. Most participants in our dataset were recruited from medical centers, substance use treatment settings, or integrated medical and substance use treatment programs in academic settings. These settings are considered high threshold due to access requirements of transportation [ref. 164], insurance [ref. 165], trust in the medical community [ref. 156,ref. 157], and time to participate. The increased challenges of conducting research with people who are incarcerated compared with people in the community [ref. 166] and the disproportionate burden of incarceration on URM groups [ref. 167] suggest reconsideration of barriers to the conduct of research with people who are incarcerated. This is a significantly understudied population and doubly marginalized by URM group and prisoner status (see the Intersectionality section).

Given the prevalence of high-threshold recruitment settings in our dataset, the dearth of research on TBIs for substance use treatment among people who identify as Hispanic or Latino or American Indian or Alaska Native individuals is unsurprising and significant. Both American Indian or Alaska Native and Hispanic or Latino individuals experience some of the worst health disparities in the United States and are more likely than White individuals to be poor and unemployed and have lower educational attainment [ref. 145,ref. 146,ref. 168]. American Indian or Alaska Native individuals are also more likely than White individuals and other URM groups to live in rural frontier settings, compounding the issue of access and inclusion [ref. 169]. Recruitment of sufficient numbers of racial and ethnic minority group participants is imperative to understanding how research affects underrepresented groups [ref. 25], with underrepresentation limiting the extent to which members of these groups benefit from advances in substance use treatment research [ref. 170]. Community-engaged recruitment strategies are needed to increase access and inclusion of URM groups [ref. 171].

Expanding TBI Substance Use Research Targeting Opioids, Stimulants, and Cannabis

Few netted studies (30/110, 27.3%) targeted opioids, stimulants (eg, methamphetamines and cocaine), and cannabis specifically. The US opioid and stimulant epidemics [ref. 172], as well as the increasing legalization of cannabis [ref. 173], create an expanding need for treatment for all people navigating problematic or disordered use [ref. 174]. However, this is particularly true for URM groups due to their marginalization in both treatment and research [ref. 175]. TBIs offer the potential to mitigate health-related disparities in care by addressing the needs of members of diverse groups and increasing access. While there is limited work focusing on people who use opioids, stimulants, and cannabis in the United States generally, our review identified the lack of research on TBIs for these drug classes that includes URM groups. The gaps in the literature on TBIs for these 3 drug classes offer enormous opportunities for promoting health equity. Several reviews have summarized the use of TBIs related to substance use [ref. 18,ref. 176–ref. 182]. However, most interventions have focused exclusively on impacting alcohol use behaviors [ref. 183].

Expanding TBI development and research beyond a heavy focus on alcohol is especially critical due to the opioid overdose epidemic. Opioid-related overdose deaths among people identifying as African American or Black and American Indian or Alaska Native individuals now outpace those of White individuals in the United States, in part because the science and resources brought to bear to fight the opioid epidemic disproportionately exclude people who identify as belonging to URM groups, especially during the early phase of the epidemic [ref. 184,ref. 185]. A total of 3.6% (4/110) of the identified studies in this scoping review focused on TBIs for opioid use disorder (OUD); all 4 were telehealth focused [ref. 186–ref. 189]. While regulations expanding telehealth care for OUD issued during the COVID-19 pandemic appear to remain in place [ref. 190], further enabling the exploration of the benefits of telehealth for OUD treatment and developing creative, effective, and culturally tailored TBIs for OUD in addition to telehealth interventions is important to expand access to OUD care.

Using Culturally Informed Theoretical Models or Equity Approaches to Knowledge Production

The theoretical models and perspectives represented in the dataset were predominantly generalizability approaches, with negligible use of culturally informed or sensitive theories or equity approaches to knowledge production (eg, sociological trust theory, community-based participatory research, public health critical race praxis, and social determinants of health) [ref. 19,ref. 163,ref. 191,ref. 192]. While the identification of the commonalities of human experience is useful, to promote health equity, researchers must explore the differential effectiveness of evidence-based interventions for URM groups.

Several netted studies (4/110, 3.6%) [ref. 34,ref. 40,ref. 41,ref. 82] used equity-promoting theories or frameworks based on community-engaged, participatory research practices in adaptations [ref. 40,ref. 41,ref. 82] or explorations of the feasibility of the adaptation [ref. 34] of evidence-based TBIs. An understanding of the power of culturally or contextually informed theories and frameworks to disrupt social mechanisms that fuel health disparities may be instructive. For example, the theoretical underpinnings for the Addiction Comprehensive Health Enhancement Support System [ref. 40,ref. 41] are based on self-determination theory [ref. 193]. One of the defining features of self-determination theory is its treatment of both the person and the social context in motivated behavior. By adapting and translating the Addiction Comprehensive Health Enhancement Support System to be linguistically and culturally relevant to Spanish-speaking Latinos in recovery, the authors support competence and autonomy by eliciting and acknowledging patients’ context and perspectives [ref. 194].

Community-based participatory research methods incorporate community member input at all phases of the research process [ref. 163]. Offering an evidence-based treatment (CBT4CBT) in an alternative setting, such as a Black church, Jordan et al [ref. 82] explored the role of context to improve access to and the efficacy of evidence-based treatments. Through engagement with the community, as well as training church staff to deliver evidence-based treatments, the authors assessed feasibility and probed necessary adaptations to the TBI to improve acceptability. Campbell et al [ref. 34] used community-engaged research methods to reveal preferences regarding delivery and presentation, including using American Indian or Alaska Native actors for voice and video components, use of stories as opposed to “academic” presentations, and inclusion of American Indian or Alaska Native cultural representation. There is substantial evidence-based work in the field of TBIs for substance use treatment. Using theories and frameworks that are sensitive to context and the diversity of human experiences, community-engaged research methods, and adaptations is possible, and efficacy is likely to be strengthened for members of underrepresented groups.

Planning to Conduct Racial and Ethnic Subgroup Analyses

Limited subpopulation analyses pose significant problems for reviews [ref. 159]. Of the 110 studies in this review, 81 (73.6%) missed an opportunity to better understand the race or ethnicity subgroup–specific implications of their findings. Thus, while it may appear that the studies identified in our review focused on TBIs with a strong evidence base, more nuanced assessments of how differentially effective these standard-bearers might be is lacking. Given the limited inclusion of members of underrepresented populations in biomedical research [ref. 195], when a sample does include sufficient representation, it is a prime opportunity for interested researchers to review data to improve our understanding of the implications for these groups. Burlew et al [ref. 25] further recommend that researchers consider within-race differences and the potential disadvantages of combining racial or ethnic minority groups in the analyses (eg, Weaver et al [ref. 196] revealed differential odds of meeting the criteria for major depressive disorder between rural Black women [lower] and urban Black women [higher]).

There is opportunity to explore clinical trials with diverse samples or large datasets that are a part of the public record to help identify moderators to improve our understanding of the differential impacts of our policies and interventions for URM groups and the multiply disadvantaged among us [ref. 197]. The NIH recently (2021) recommended that investigators should not control for the contextual variables (eg, neighborhoods and employment opportunities) that are the drivers of inequity but, rather, that these factors be explicitly studied. Systems of oppression are inherently bound together—the intersection of multiple identities (eg, gender and race) within social systems of power may compound and synergistically exacerbate experiences of health disparity [ref. 198].

Adapting TBIs With Demonstrated Effectiveness for Examination With URM Groups

Related to the aforementioned opportunity for growth regarding planned subgroup analyses, another opportunity for interested researchers is to adapt TBIs with demonstrated effectiveness for examination among URM groups. Many of the programs of research netted in this review underscore this opportunity. For example, Paris et al [ref. 38] described the primary outcomes of a randomized clinical trial comparing a culturally adapted version of CBT4CBT-Spanish to standard outpatient mental health and addiction treatment in a heterogeneous population of treatment-seeking Latino adults. Their rationale for undertaking this research included consideration of previous findings on the efficacy, safety, and durability of the existing English-language versions of CBT4CBT when added to standard outpatient treatment. There is no shortage of TBIs for substance use disorders; however, as this review reveals, there is a shortage of understanding which among the many might be efficacious for URM groups.

Considering Intersectionality

While seeking to characterize the range and nature of TBIs for substance use treatment among people who identify as African American or Black, Hispanic or Latino, and American Indian or Alaska Native individuals, we discovered that most of the studies (85/110, 77.3%) included historically underserved populations, such as pregnant or perinatal women, people living with HIV or AIDS, adolescents or youth, youth exiting foster care, people who are justice or court involved, people who are unhoused, and veterans. In addition, most of the participants across these studies were impacted by multiple socioeconomic challenges, notably income, housing, education, and health insurance. A recent literature review on multiple disadvantages in relation to telehealth [ref. 199] identified intersectionality theory [ref. 200] as an approach that the authors felt might help account for digital disparities. Intersectionality theory posits that considering a single axis of inequality is limited and that considering disadvantage on multiple axes simultaneously is needed [ref. 201]. Applied to digital health disparities, this theory suggests the hypothesis that our individual identities and lived experiences are unique and multidimensional and that we will or will not use TBIs based on our unique identities and experiences rather than due to our identification with single categories such as race, age, gender, or disability. Per intersectionality theory, addressing health inequities will entail an increased understanding of how various structural and social determinants of health interact. To achieve this increased understanding, we must work with individuals, families, groups, and communities to understand what shapes their experiences of advantage and disadvantage. The import of this theory cannot be understated for the data that we collected. To capture intersectionality, a first challenge for researchers working in this space and beyond is to take a step back, digest the large-scale studies that appear to have uniform messages about broad factors associated with efficacy or effectiveness applicable to all [ref. 202], and commit to collecting and reporting data related to multiple categories at once (eg, race, sex, and income). A second challenge is to combine this knowledge with tailored implementation strategies, acknowledging how different aspects of disadvantage related to social determinants of health interact in individual lives, impacting access, adoption, and effectiveness of TBIs for substance use. Dr Nora Volkow, the director of the National Institute on Drug Abuse, recently blogged that “measuring social determinants of health can help researchers better design treatment interventions and services, as well as make addiction care more equitable. Research in other areas of medicine has already revealed the distorting effects of failure to take that step” [ref. 203]. We must strive to conduct research that promotes health equity for all.

Future Research

We acknowledge researchers who have been working in the health equity field that dates back more than a century [ref. 148]. While most of our team members identify as White, we acknowledge the historical damage posed by many White allies and aspire beyond “health equity tourism” [ref. 148,ref. 204]. We aim to be solution focused, collaborating with deeply knowledgeable equity researchers to build on the knowledge presented herein. In this spirit, we seek to partner with scholars from underrepresented groups on future research exploring optimal practices for research with diverse and underrepresented groups; race and ethnicity consciousness; and effectiveness of TBIs for people who identify as African American or Black, Hispanic or Latino, and American Indian or Alaska Native individuals based on this scoping review. We encourage readers to take note of the research opportunities implied in the Opportunities for Growth section as well.

Limitations

Several limitations warrant attention. First, our eligibility criteria of samples of ≥50% of URM group members may have precluded exploration of literature with the potential to provide further insights to promote health equity in the TBI for substance use treatment arena. Second, the threshold for designation of higher appraisal or confidence versus lower appraisal confidence of 90% of members of a single URM group in the study samples was an arbitrary cutoff and, as such, highlights the guidance nature of critical appraisals. Per a recent publication on critical appraisals, “decisions on whether a study is considered weak, moderate, or strong are based on arbitrary cut-off scores” [ref. 205]. In theory, any cutoff of >50% would show that most participants were from a single URM group, although 90% could be considered a conservative cutoff to ensure that the results have direct implications for that group. The appraisal is intended as guidance or a gauge of the confidence that a reader should reasonably have that the study in question may have interpretable findings for a particular URM group. Third, to avoid intervention-generated inequalities and ensure that an equity lens is applied in the conduct, reporting, and use of research, an oft-cited recommendation is for researchers to report relevant sociodemographic characteristics of the samples. These include the PROGRESS-Plus (place of residence, race, ethnicity, language, occupation, gender or sex, religion, educational level, SES, social capital) factors of place of residence, race, ethnicity, language, occupation, gender or sex, religion, educational level, SES, age, disability, and sexual orientation [ref. 19,ref. 206]. This framework functions as a reminder that understanding health equity encompasses numerous factors beyond race and ethnicity that impact intervention access, adherence, adoption, and effectiveness. While our review focused on race or ethnicity, we acknowledge the importance of attending to a broader array of demographic variables to ensure that TBIs do not fall into the trap of inadvertently contributing to increasing health inequities, increasing the gap between the most and least advantaged. Fourth, a general limitation of the TBI research included in this review was the low SES among participants of the netted samples, as well as the high-threshold venues for recruitment. Both are filters that limit a more thorough understanding of the potential of TBIs to promote health equity.

Conclusions

Through this review, we sought to provide context, insights, and direction for researchers working to develop and evaluate digital technology substance use interventions while promoting health equity. An NIH recommendation on enhancing health disparity research suggests that we must go beyond “ticking the box” when including racial and ethnic minority groups in research [ref. 158]. Instead, underrepresented populations must be the focus of studies, or at the very least, the studies must be race and ethnicity sensitive [ref. 197]. As we do not all experience equity in health, we must resist the temptation to use universal instruments to attain universal ends; one size has never fit all [ref. 207]. This scoping review was conducted in the spirit of this recommendation. We sought to focus attention on those studies that included members of underrepresented groups and, further, those that gave voice to these people through race- and ethnicity-conscious research or end-user engagement. A noted sociologist who writes about technology and its potential to exacerbate inequities suggests that “the ways we engineer the material world reflects and reinforces (but could also be used to subvert) social hierarchies” [ref. 208]. It is our fervent hope that insights into the engineering of TBIs for substance use treatment for URM groups can and will be used to erode structural racism in health care.

References

1. S Matsuzaka, M Knapp. Anti-racism and substance use treatment: addiction does not discriminate, but do we?. J Ethn Subst Abuse, 2019. [DOI | PubMed]
2. Treatment Episode Data Set (TEDS): 2020 Admissions To And Discharges From Publicly Funded Substance Use Treatment Facilities. Substance Abuse and Mental Health Services Administration
3. N Volkow. Making addiction treatment more realistic and pragmatic: the perfect should not be the enemy of the good. National Institute on Drug Abuse, 2022
4. Highlighted population slides. SAMSHA
5. J Mennis, GJ Stahler. Racial and ethnic disparities in outpatient substance use disorder treatment episode completion for different substances. J Subst Abuse Treat, 2016. [DOI | PubMed]
6. J Mennis, GJ Stahler, SA El Magd, DA Baron. How long does it take to complete outpatient substance use disorder treatment? Disparities among Blacks, Hispanics, and Whites in the US. Addict Behav, 2019. [DOI | PubMed]
7. M Pinedo. A current re-examination of racial/ethnic disparities in the use of substance abuse treatment: do disparities persist?. Drug Alcohol Depend, 2019. [DOI | PubMed]
8. GJ Stahler, J Mennis. Treatment outcome disparities for opioid users: are there racial and ethnic differences in treatment completion across large US metropolitan areas?. Drug Alcohol Depend, 2018. [DOI | PubMed]
9. NR Whitesell, J Beals, CB Crow, CM Mitchell, DK Novins. Epidemiology and etiology of substance use among American Indians and Alaska Natives: risk, protection, and implications for prevention. Am J Drug Alcohol Abuse, 2012. [DOI | PubMed]
10. MA Enoch, BJ Albaugh. Review: genetic and environmental risk factors for alcohol use disorders in American Indians and Alaskan Natives. Am J Addict, 2017. [DOI | PubMed]
11. MB Emert, Z Giano. A comparison of alcohol and commercial tobacco use in populous American Indian/Alaska Native states. Drug Alcohol Depend, 2023. [DOI | PubMed]
12. J Burger, M Kapron. Drug policy and indigenous peoples. Health Hum Rights, 2017. [PubMed]
13. P Farahmand, A Arshed, MV Bradley. Systemic racism and substance use disorders. Psychiatr Ann, 2020. [DOI]
14. B Saloner, B Lê Cook. Blacks and Hispanics are less likely than whites to complete addiction treatment, largely due to socioeconomic factors. Health Aff (Millwood), 2013. [DOI | PubMed]
15. AB Geller, DE Polsky, SP Burke. Federal Policy to Advance Racial, Ethnic, and Tribal Health Equity, 2023
16. AW Blume. Advances in substance abuse prevention and treatment interventions among racial, ethnic, and sexual minority populations. Alcohol Res, 2016. [PubMed]
17. A Jordan, S Quainoo, C Nich, TA Babuscio, MC Funaro, KM Carroll. Racial and ethnic differences in alcohol, cannabis, and illicit substance use treatment: a systematic review and narrative synthesis of studies done in the USA. Lancet Psychiatry, 2022. [DOI | PubMed]
18. LA Marsch, H Guarino, M Acosta, Y Aponte-Melendez, C Cleland, M Grabinski, R Brady, J Edwards. Web-based behavioral treatment for substance use disorders as a partial replacement of standard methadone maintenance treatment. J Subst Abuse Treat, 2014. [DOI | PubMed]
19. TC Veinot, H Mitchell, JS Ancker. Good intentions are not enough: how informatics interventions can worsen inequality. J Am Med Inform Assoc, 2018. [DOI | PubMed]
20. JP Cerdeña, LM Rivera, JM Spak. Intergenerational trauma in Latinxs: a scoping review. Soc Sci Med, 2021. [DOI | PubMed]
21. S Hamed, H Bradby, BM Ahlberg, S Thapar-Björkert. Racism in healthcare: a scoping review. BMC Public Health, 2022. [DOI | PubMed]
22. JM Metzl, H Hansen. Structural competency: theorizing a new medical engagement with stigma and inequality. Soc Sci Med, 2014. [DOI | PubMed]
23. AK Burlew, VC Copeland, C Ahuama-Jonas, DA Calsyn. Does cultural adaptation have a role in substance abuse treatment?. Soc Work Public Health, 2013. [DOI | PubMed]
24. AK Burlew, BJ Peteet, C McCuistian, BD Miller-Roenigk. Best practices for researching diverse groups. Am J Orthopsychiatry, 2019. [DOI | PubMed]
25. K Burlew, C McCuistian, J Szapocznik. Racial/ethnic equity in substance use treatment research: the way forward. Addict Sci Clin Pract, 2021. [DOI | PubMed]
26. E Montague, J Perchonok. Health and wellness technology use by historically underserved health consumers: systematic review. J Med Internet Res, 2012. [DOI | PubMed]
27. AC Tricco, E Lillie, W Zarin, KK O’Brien, H Colquhoun, D Levac, D Moher, MD Peters, T Horsley, L Weeks, S Hempel, EA Akl, C Chang, J McGowan, L Stewart, L Hartling, A Aldcroft, MG Wilson, C Garritty, S Lewin, CM Godfrey, MT Macdonald, EV Langlois, K Soares-Weiser, J Moriarty, T Clifford, Ö Tunçalp, SE Straus. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med, 2018. [DOI | PubMed]
28. EG Hichborn, SK Moore, PR Gauthier, NO Agosti, KD Bell, JS Boggis, CA Lambert-Harris, EC Saunders, AM Turner, BM McLeman, LA Marsch. Technology-based interventions in substance use treatment to promote health equity among people who identify as African American/black, Hispanic/Latinx, and American Indian/Alaskan native: protocol for a scoping review. JMIR Res Protoc, 2022. [DOI | PubMed]
29. MG Peters, CM Godfrey, H Khalil, P McInerney, D Parker, CB Soares. Guidance for conducting systematic scoping reviews. Int J Evid Based Healthc, 2015. [DOI | PubMed]
30. SJ Huey Jr, AJ Polo. Evidence-based psychosocial treatments for ethnic minority youth. J Clin Child Adolesc Psychol, 2008. [DOI | PubMed]
31. F Taj, MC Klein, A van Halteren. Digital health behavior change technology: bibliometric and scoping review of two decades of research. JMIR Mhealth Uhealth, 2019. [DOI | PubMed]
32. E Hichborn, A Turner, S Moore, P Gauthier, K Bell, L Montgomery, J Boggis, C Lambert-Harris, E Saunders, J Dallery, B McLeman, L Marsch. Technology-based interventions in tobacco use treatment among people who identify as African American/Black, Hispanic/Latina/o, and American Indian/Alaska Native: scoping review. J Med Internet Res, 2024. [DOI | PubMed]
33. M Ouzzani, H Hammady, Z Fedorowicz, A Elmagarmid. Rayyan-a web and mobile app for systematic reviews. Syst Rev, 2016. [DOI | PubMed]
34. AN Campbell, E Turrigiano, M Moore, GM Miele, T Rieckmann, M Hu, F Kropp, R Ringor-Carty, EV Nunes. Acceptability of a web-based community reinforcement approach for substance use disorders with treatment-seeking American Indians/Alaska Natives. Community Ment Health J, 2015. [DOI | PubMed]
35. JR Gorman, JD Clapp, D Calac, C Kolander, C Nyquist, CD Chambers. Creating a culturally appropriate web-based behavioral intervention for American Indian/Alaska Native women in Southern California: the healthy women healthy Native nation study. Am Indian Alsk Native Ment Health Res, 2013. [DOI]
36. AC Montag, ML Dusek, ML Ortega, A Camp-Mazzetti, DJ Calac, CD Chambers. Tailoring an alcohol intervention for American Indian Alaska native women of childbearing age: listening to the community. Alcohol Clin Exp Res, 2017. [DOI | PubMed]
37. RK Legha, L Moore, R Ling, D Novins, J Shore. Telepsychiatry in an Alaska Native residential substance abuse treatment program. Telemed J E Health, 2020. [DOI | PubMed]
38. M Paris, M Silva, L Añez-Nava, Y Jaramillo, BD Kiluk, MA Gordon, C Nich, T Frankforter, K Devore, SA Ball, KM Carroll. Culturally adapted, web-based cognitive behavioral therapy for Spanish-speaking individuals with substance use disorders: a randomized clinical trial. Am J Public Health, 2018. [DOI | PubMed]
39. E Aharonovich, ML Hatzenbuehler, B Johnston, A O’Leary, J Morgenstern, ML Wainberg, P Yao, JE Helzer, DS Hasin. A low-cost, sustainable intervention for drinking reduction in the HIV primary care setting. AIDS Care, 2006. [DOI | PubMed]
40. J Muroff, W Robinson, D Chassler, LM López, E Gaitan, L Lundgren, C Guauque, S Dargon-Hart, E Stewart, D Dejesus, K Johnson, K Pe-Romashko, DH Gustafson. Use of a smartphone recovery tool for Latinos with co-occurring alcohol and other drug disorders and mental disorders. J Dual Diagn, 2017. [DOI | PubMed]
41. J Muroff, W Robinson, D Chassler, LM López, L Lundgren, C Guauque, S Dargon-Hart, E Stewart, D Dejesus, K Johnson, K Pe-Romashko, DH Gustafson. An outcome study of the CASA-CHESS smartphone relapse prevention tool for Latinx Spanish-speakers with substance use disorders. Subst Use Misuse, 2019. [DOI | PubMed]
42. KC Osilla, EJ D’Amico, CM Díaz-Fuentes, M Lara, KE Watkins. Multicultural web-based motivational interviewing for clients with a first-time DUI offense. Cultur Divers Ethnic Minor Psychol, 2012. [DOI | PubMed]
43. MB Nayak, RA Korcha, LA Kaskutas, LA Avalos. Erratum: feasibility and acceptability of a novel, computerized screening and brief intervention (SBI) for alcohol and sweetened beverage use in pregnancy. BMC Pregnancy Childbirth, 2015. [DOI | PubMed]
44. MB Nayak, LA Kaskutas, AA Mericle. Randomized trial of an innovative electronic screening and brief intervention for reducing drinking among women of childbearing age. J Addict Med, 2019. [DOI | PubMed]
45. WS Comulada, M Lightfoot, D Swendeman, C Grella, N Wu. Compliance to cell phone-based EMA among Latino youth in outpatient treatment. J Ethn Subst Abuse, 2015. [DOI | PubMed]
46. M Millery, BP Kleinman, NL Polissar, RB Millman, M Scimeca. Detoxification as a gateway to long-term treatment: assessing two interventions. J Subst Abuse Treat, 2002. [DOI | PubMed]
47. PM Sanjuan, MR Pearson, C Poremba, HD Amaro, L Leeman. An ecological momentary assessment study examining posttraumatic stress disorder symptoms, prenatal bonding, and substance use among pregnant women. Drug Alcohol Depend, 2019. [DOI | PubMed]
48. KJ Trudeau, J Ainscough, S Charity. Technology in treatment: are adolescents and counselors interested in online relapse prevention?. Child Youth Care Forum, 2012. [DOI | PubMed]
49. M Tolou-Shams, J Yonek, K Galbraith, E Bath. Text messaging to enhance behavioral health treatment engagement among justice-involved youth: qualitative and user testing study. JMIR Mhealth Uhealth, 2019. [DOI | PubMed]
50. J Mullen, SR Ryan, CW Mathias, DM Dougherty. Feasibility of a computer-assisted alcohol screening, brief intervention and referral to treatment program for DWI offenders. Addict Sci Clin Pract, 2015. [DOI | PubMed]
51. E Burner, M Zhang, S Terp, K Ford Bench, J Lee, CN Lam, JR Torres, M Menchine, S Arora. Feasibility and acceptability of a text message-based intervention to reduce overuse of alcohol in emergency department patients: controlled proof-of-concept trial. JMIR Mhealth Uhealth, 2020. [DOI | PubMed]
52. ID Aronson, A Bennett, LA Marsch, TC Bania. Mobile technology to increase HIV/HCV testing and overdose prevention/response among people who inject drugs. Front Public Health, 2017. [DOI | PubMed]
53. JM Braciszewski, GK Tzilos Wernette, RS Moore, TB Tran, BC Bock, RL Stout, P Chamberlain, A Vose-O’Neal. Developing a tailored substance use intervention for youth exiting foster care. Child Abuse Negl, 2018. [DOI | PubMed]
54. G Tzilos Wernette, M Plegue, CW Kahler, A Sen, C Zlotnick. A pilot randomized controlled trial of a computer-delivered brief intervention for substance use and risky sex during pregnancy. J Womens Health (Larchmt), 2018. [DOI | PubMed]
55. KM Carroll, SA Ball, S Martino, C Nich, TA Babuscio, KF Nuro, MA Gordon, GA Portnoy, BJ Rounsaville. Computer-assisted delivery of cognitive-behavioral therapy for addiction: a randomized trial of CBT4CBT. Am J Psychiatry, 2008. [DOI | PubMed]
56. DE Sugarman, C Nich, KM Carroll. Coping strategy use following computerized cognitive-behavioral therapy for substance use disorders. Psychol Addict Behav, 2010. [DOI | PubMed]
57. BD Kiluk, C Nich, T Babuscio, KM Carroll. Quality versus quantity: acquisition of coping skills following computerized cognitive-behavioral therapy for substance use disorders. Addiction, 2010. [DOI | PubMed]
58. BD Kiluk, C Nich, KM Carroll. Relationship of cognitive function and the acquisition of coping skills in computer assisted treatment for substance use disorders. Drug Alcohol Depend, 2011. [DOI | PubMed]
59. RG Thompson, C Aivadyan, M Stohl, E Aharonovich, DS Hasin. Smartphone application plus brief motivational intervention reduces substance use and sexual risk behaviors among homeless young adults: results from a randomized controlled trial. Psychol Addict Behav, 2020. [DOI | PubMed]
60. F Muench, RA Weiss, A Kuerbis, J Morgenstern. Developing a theory driven text messaging intervention for addiction care with user driven content. Psychol Addict Behav, 2013. [DOI | PubMed]
61. KS Ingersoll, L Farrell-Carnahan, J Cohen-Filipic, CJ Heckman, SD Ceperich, J Hettema, G Marzani-Nissen. A pilot randomized clinical trial of two medication adherence and drug use interventions for HIV+ crack cocaine users. Drug Alcohol Depend, 2011. [DOI | PubMed]
62. F Alemi, M Haack, S Nemes, A Harge, H Baghi. Impact of online counseling on drug use: a pilot study. Qual Manag Health Care, 2010. [DOI | PubMed]
63. SJ Ondersma, SK Chase, DS Svikis, CR Schuster. Computer-based brief motivational intervention for perinatal drug use. J Subst Abuse Treat, 2005. [DOI | PubMed]
64. SJ Ondersma, DS Svikis, CR Schuster. Computer-based brief intervention a randomized trial with postpartum women. Am J Prev Med, 2007. [DOI | PubMed]
65. SJ Ondersma, ER Grekin, D Svikis. The potential for technology in brief interventions for substance use, and during-session prediction of computer-delivered brief intervention response. Subst Use Misuse, 2011. [DOI | PubMed]
66. SJ Ondersma, DS Svikis, LR Thacker, JR Beatty, N Lockhart. Computer-delivered screening and brief intervention (e-SBI) for postpartum drug use: a randomized trial. J Subst Abuse Treat, 2014. [DOI | PubMed]
67. GK Tzilos, RJ Sokol, SJ Ondersma. A randomized phase I trial of a brief computer-delivered intervention for alcohol use during pregnancy. J Womens Health (Larchmt), 2011. [DOI | PubMed]
68. SJ Ondersma, JR Beatty, DS Svikis, RC Strickler, GK Tzilos, G Chang, GW Divine, AR Taylor, RJ Sokol. Computer-delivered screening and brief intervention for alcohol use in pregnancy: a pilot randomized trial. Alcohol Clin Exp Res, 2015. [DOI | PubMed]
69. SA Pollick, JR Beatty, RJ Sokol, RC Strickler, G Chang, DS Svikis, GK Tzilos, SJ Ondersma. Acceptability of a computerized brief intervention for alcohol among abstinent but at-risk pregnant women. Subst Abus, 2015. [DOI | PubMed]
70. SJ Ondersma, DS Svikis, LR Thacker, JR Beatty, N Lockhart. A randomised trial of a computer-delivered screening and brief intervention for postpartum alcohol use. Drug Alcohol Rev, 2016. [DOI | PubMed]
71. S Martino, SJ Ondersma, A Forray, TA Olmstead, K Gilstad-Hayden, HB Howell, T Kershaw, KA Yonkers. A randomized controlled trial of screening and brief interventions for substance misuse in reproductive health. Am J Obstet Gynecol, 2018. [DOI]
72. A Forray, S Martino, K Gilstad-Hayden, T Kershaw, S Ondersma, T Olmstead, KA Yonkers. Assessment of an electronic and clinician-delivered brief intervention on cigarette, alcohol and illicit drug use among women in a reproductive healthcare clinic. Addict Behav, 2019. [DOI | PubMed]
73. AM Loree, KA Yonkers, SJ Ondersma, K Gilstad-Hayden, S Martino. Comparing satisfaction, alliance and intervention components in electronically delivered and in-person brief interventions for substance use among childbearing-aged women. J Subst Abuse Treat, 2019. [DOI | PubMed]
74. KA Yonkers, JI Dailey, K Gilstad-Hayden, SJ Ondersma, A Forray, TA Olmstead, S Martino. Abstinence outcomes among women in reproductive health centers administered clinician or electronic brief interventions. J Subst Abuse Treat, 2020. [DOI | PubMed]
75. SJ Ondersma, DS Svikis, C Thacker, K Resnicow, JR Beatty, J Janisse, K Puder. Computer-delivered indirect screening and brief intervention for drug use in the perinatal period: a randomized trial. Drug Alcohol Depend, 2018. [DOI | PubMed]
76. JM Braciszewski, GK Tzilos Wernette, RS Moore, BC Bock, RL Stout, P Chamberlain. A pilot randomized controlled trial of a technology-based substance use intervention for youth exiting foster care. Child Youth Serv Rev, 2018. [DOI | PubMed]
77. SJ Ondersma, JR Beatty, KS Puder, J Janisse, DS Svikis. Feasibility and acceptability of e-screening and brief intervention and tailored text messaging for marijuana use in pregnancy. J Womens Health (Larchmt), 2019. [DOI | PubMed]
78. BD Kiluk, KA Devore, MB Buck, C Nich, TL Frankforter, DM LaPaglia, BT Yates, MA Gordon, KM Carroll. Randomized trial of computerized cognitive behavioral therapy for alcohol use disorders: efficacy as a virtual stand-alone and treatment add-on compared with standard outpatient treatment. Alcohol Clin Exp Res, 2016. [DOI | PubMed]
79. BD Kiluk, TL Frankforter, M Cusumano, C Nich, KM Carroll. Change in DSM-5 alcohol use disorder criteria count and severity level as a treatment outcome indicator: results from a randomized trial. Alcohol Clin Exp Res, 2018. [DOI]
80. BD Kiluk, C Nich, MB Buck, KA Devore, TL Frankforter, DM LaPaglia, SB Muvvala, KM Carroll. Randomized clinical trial of computerized and clinician-delivered CBT in comparison with standard outpatient treatment for substance use disorders: primary within-treatment and follow-up outcomes. Am J Psychiatry, 2018. [DOI | PubMed]
81. CR Roos, KM Carroll, C Nich, T Frankforter, BD Kiluk. Short- and long-term changes in substance-related coping as mediators of in-person and computerized CBT for alcohol and drug use disorders. Drug Alcohol Depend, 2020. [DOI | PubMed]
82. A Jordan, T Babuscio, C Nich, KM Carroll. A feasibility study providing substance use treatment in the Black church. J Subst Abuse Treat, 2021. [DOI | PubMed]
83. DS Hasin, E Aharonovich, A O’Leary, E Greenstein, M Pavlicova, S Arunajadai, R Waxman, M Wainberg, J Helzer, B Johnston. Reducing heavy drinking in HIV primary care: a randomized trial of brief intervention, with and without technological enhancement. Addiction, 2013. [DOI | PubMed]
84. DS Hasin, E Aharonovich, E Greenstein. HealthCall for the smartphone: technology enhancement of brief intervention in HIV alcohol dependent patients. Addict Sci Clin Pract, 2014. [DOI | PubMed]
85. E Aharonovich, E Greenstein, A O’Leary, B Johnston, SG Seol, DS Hasin. HealthCall: technology-based extension of motivational interviewing to reduce non-injection drug use in HIV primary care patients – a pilot study. AIDS Care, 2012. [DOI | PubMed]
86. E Aharonovich, A Sarvet, M Stohl, D DesJarlais, S Tross, T Hurst, A Urbina, D Hasin. Reducing non-injection drug use in HIV primary care: a randomized trial of brief motivational interviewing, with and without HealthCall, a technology-based enhancement. J Subst Abuse Treat, 2017. [DOI | PubMed]
87. E Aharonovich, M Stohl, D Cannizzaro, D Hasin. HealthCall delivered via smartphone to reduce co-occurring drug and alcohol use in HIV-infected adults: a randomized pilot trial. J Subst Abuse Treat, 2017. [DOI | PubMed]
88. RM Cunningham, MA Walton, A Goldstein, ST Chermack, JT Shope, CR Bingham, MA Zimmerman, FC Blow. Three-month follow-up of brief computerized and therapist interventions for alcohol and violence among teens. Acad Emerg Med, 2009. [DOI | PubMed]
89. MA Walton, ST Chermack, JT Shope, CR Bingham, MA Zimmerman, FC Blow, RM Cunningham. Effects of a brief intervention for reducing violence and alcohol misuse among adolescents: a randomized controlled trial. JAMA, 2010. [DOI | PubMed]
90. MA Walton, K Bohnert, S Resko, KL Barry, ST Chermack, RA Zucker, MA Zimmerman, BM Booth, FC Blow. Computer and therapist based brief interventions among cannabis-using adolescents presenting to primary care: one year outcomes. Drug Alcohol Depend, 2013. [DOI | PubMed]
91. FC Blow, MA Walton, AS Bohnert, RV Ignacio, S Chermack, RM Cunningham, BM Booth, M Ilgen, KL Barry. A randomized controlled trial of brief interventions to reduce drug use among adults in a low-income urban emergency department: the HealthiER You study. Addiction, 2017. [DOI | PubMed]
92. R Waller, EE Bonar, AC Fernandez, MA Walton, ST Chermack, RM Cunningham, FC Blow. Exploring the components of an efficacious computer brief intervention for reducing marijuana use among adults in the emergency department. J Subst Abuse Treat, 2019. [DOI | PubMed]
93. LE Drislane, R Waller, ME Martz, EE Bonar, MA Walton, ST Chermack, FC Blow. Therapist and computer-based brief interventions for drug use within a randomized controlled trial: effects on parallel trajectories of alcohol use, cannabis use and anxiety symptoms. Addiction, 2020. [DOI | PubMed]
94. ML Dennis, CK Scott, RR Funk, L Nicholson. A pilot study to examine the feasibility and potential effectiveness of using smartphones to provide recovery support for adolescents. Subst Abus, 2015. [DOI | PubMed]
95. CK Scott, K Johnson, ML Dennis. Using mobile phone technology to provide recovery support for women offenders. Telemed J E Health, 2013. [DOI | PubMed]
96. CK Scott, ML Dennis, KA Johnson, CE Grella. A randomized clinical trial of smartphone self-managed recovery support services. J Subst Abuse Treat, 2020. [DOI | PubMed]
97. KL Preston, ML Jobes, KA Phillips, DH Epstein. Real-time assessment of alcohol drinking and drug use in opioid-dependent polydrug users. Behav Pharmacol, 2016. [DOI | PubMed]
98. KL Preston, WJ Kowalczyk, KA Phillips, ML Jobes, M Vahabzadeh, JL Lin, M Mezghanni, DH Epstein. Context and craving during stressful events in the daily lives of drug-dependent patients. Psychopharmacology (Berl), 2017. [DOI | PubMed]
99. KL Preston, WJ Kowalczyk, KA Phillips, ML Jobes, M Vahabzadeh, JL Lin, M Mezghanni, DH Epstein. Before and after: craving, mood, and background stress in the hours surrounding drug use and stressful events in patients with opioid-use disorder. Psychopharmacology (Berl), 2018. [DOI | PubMed]
100. KL Preston, JR Schroeder, WJ Kowalczyk, KA Phillips, ML Jobes, M Dwyer, M Vahabzadeh, J Lin, M Mezghanni, DH Epstein. End-of-day reports of daily hassles and stress in men and women with opioid-use disorder: relationship to momentary reports of opioid and cocaine use and stress. Drug Alcohol Depend, 2018. [DOI | PubMed]
101. CJ Reback, DL Grant, JB Fletcher, CM Branson, S Shoptaw, JR Bowers, M Charania, G Mansergh. Text messaging reduces HIV risk behaviors among methamphetamine-using men who have sex with men. AIDS Behav, 2012. [DOI | PubMed]
102. CJ Reback, JB Fletcher, S Shoptaw, G Mansergh. Exposure to theory-driven text messages is associated with HIV risk reduction among methamphetamine-using men who have sex with men. AIDS Behav, 2015. [DOI | PubMed]
103. CJ Reback, JB Fletcher, DA Swendeman, M Metzner. Theory-based text-messaging to reduce methamphetamine use and HIV sexual risk behaviors among men who have sex with men: automated unidirectional delivery outperforms bidirectional peer interactive delivery. AIDS Behav, 2019. [DOI | PubMed]
104. AC Brooks, D Ryder, D Carise, KC Kirby. Feasibility and effectiveness of computer-based therapy in community treatment. J Subst Abuse Treat, 2010. [DOI | PubMed]
105. AJ Budney, C Stanger, JM Tilford, EB Scherer, PC Brown, Z Li, Z Li, DD Walker. Computer-assisted behavioral therapy and contingency management for cannabis use disorder. Psychol Addict Behav, 2015. [DOI | PubMed]
106. K Delrahim-Howlett, CD Chambers, JD Clapp, R Xu, K Duke, RJ Moyer 3rd, D Van Sickle. Web-based assessment and brief intervention for alcohol use in women of childbearing potential: a report of the primary findings. Alcohol Clin Exp Res, 2011. [DOI | PubMed]
107. B Tofighi, E Grossman, S Bereket, J D Lee. Text message content preferences to improve buprenorphine maintenance treatment in primary care. J Addict Dis, 2016. [DOI | PubMed]
108. B Tofighi, F Grazioli, S Bereket, E Grossman, Y Aphinyanaphongs, JD Lee. Text message reminders for improving patient appointment adherence in an office-based buprenorphine program: a feasibility study. Am J Addict, 2017. [DOI | PubMed]
109. B Tofighi, J McNeely, D Walzer, K Fansiwala, A Demner, CS Chaudhury, I Subudhi, D Schatz, T Reed, N Krawczyk. A telemedicine buprenorphine clinic to serve New York City: initial evaluation of the NYC public hospital system’s initiative to expand treatment access during the COVID-19 pandemic. J Addict Med, 2022. [DOI | PubMed]
110. KC Osilla, SM Paddock, TJ Leininger, EJ D’Amico, BA Ewing, KE Watkins. A pilot study comparing in-person and web-based motivational interviewing among adults with a first-time DUI offense. Addict Sci Clin Pract, 2015. [DOI | PubMed]
111. DP Kennedy, KC Osilla, SB Hunter, D Golinelli, E Maksabedian Hernandez, JS Tucker. A pilot test of a motivational interviewing social network intervention to reduce substance use among housing first residents. J Subst Abuse Treat, 2018. [DOI | PubMed]
112. C Dawson Rose, YP Cuca, E Kamitani, S Eng, R Zepf, J Draughon, P Lum. Using interactive web-based screening, brief intervention and referral to treatment in an urban, safety-net HIV clinic. AIDS Behav, 2015. [DOI]
113. C Dawson-Rose, JE Draughon, Y Cuca, R Zepf, E Huang, BA Cooper, PJ Lum. Changes in specific substance involvement scores among SBIRT recipients in an HIV primary care setting. Addict Sci Clin Pract, 2017. [DOI | PubMed]
114. P Saberi, C Dawson Rose, AR Wootton, K Ming, D Legnitto, M Jeske, LM Pollack, MO Johnson, VA Gruber, TB Neilands. Use of technology for delivery of mental health and substance use services to youth living with HIV: a mixed-methods perspective. AIDS Care, 2020. [DOI | PubMed]
115. KS Ingersoll, RA Dillingham, JE Hettema, M Conaway, J Freeman, G Reynolds, S Hosseinbor. Pilot RCT of bidirectional text messaging for ART adherence among nonurban substance users with HIV. Health Psychol, 2015. [DOI | PubMed]
116. LA Shrier, A Rhoads, P Burke, C Walls, EA Blood. Real-time, contextual intervention using mobile technology to reduce marijuana use among youth: a pilot study. Addict Behav, 2014. [DOI | PubMed]
117. LA Shrier, PJ Burke, M Kells, EA Scherer, V Sarda, C Jonestrask, Z Xuan, SK Harris. Pilot randomized trial of MOMENT, a motivational counseling-plus-ecological momentary intervention to reduce marijuana use in youth. Mhealth, 2018. [DOI | PubMed]
118. D Swendeman, S Sumstine, E Aguilar, PM Gorbach, WS Comulada, L Gelberg. Feasibility and acceptability of mobile phone self-monitoring and automated feedback to enhance telephone coaching for people with risky substance use: the QUIT-mobile pilot study. J Addict Med, 2021. [DOI | PubMed]
119. BC Frueh, S Henderson, H Myrick. Telehealth service delivery for persons with alcoholism. J Telemed Telecare, 2005. [DOI | PubMed]
120. WM Wechsberg, FA Browne, W Poulton, RM Ellerson, A Simons-Rudolph, D Haller. Adapting an evidence-based HIV prevention intervention for pregnant African-American women in substance abuse treatment. Subst Abuse Rehabil, 2011. [DOI | PubMed]
121. M Brusoski, D Rosen. Health promotion using tablet technology with older adult African American methadone clients: a case study. J Technol Hum Serv, 2015. [DOI]
122. C Welsh. Acceptability of the use of cellular telephone and computer pictures/video for "pill counts" in buprenorphine maintenance treatment. J Opioid Manag, 2016. [DOI | PubMed]
123. M Jaconis, EJ Santa Ana, TK Killeen, CL Badour, SE Back. Concurrent treatment of PTSD and alcohol use disorder via telehealth in a female Iraq veteran. Am J Addict, 2017. [DOI | PubMed]
124. TP Palfai, JL Taylor, R Saitz, MP Kratzer, JD Otis, JA Bernstein. Development of a tailored, telehealth intervention to address chronic pain and heavy drinking among people with HIV infection: integrating perspectives of patients in HIV care. Addict Sci Clin Pract, 2019. [DOI | PubMed]
125. M Castillo, B Conte, S Hinkes, M Mathew, CJ Na, A Norindr, DP Serota, DW Forrest, AR Deshpande, TS Bartholomew, HE Tookes. Implementation of a medical student-run telemedicine program for medications for opioid use disorder during the COVID-19 pandemic. Harm Reduct J, 2020. [DOI | PubMed]
126. NJ Mehtani, JT Ristau, H Snyder, C Surlyn, J Eveland, S Smith-Bernardin, KR Knight. COVID-19: a catalyst for change in telehealth service delivery for opioid use disorder management. Subst Abus, 2021. [DOI | PubMed]
127. DT O’Gurek. Designing and evaluating COVID-19 protocols for an office-based opioid treatment program in an urban underserved setting. J Am Board Fam Med, 2021. [DOI | PubMed]
128. ME Saladin, KT Brady, K Graap, BO Rothbaum. A preliminary report on the use of virtual reality technology to elicit craving and cue reactivity in cocaine dependent individuals. Addict Behav, 2006. [DOI | PubMed]
129. MS Gordon, SB Carswell, M Schadegg, K Mangen, K Merkel, S Tangires, FJ Vocci. Avatar-assisted therapy: a proof-of-concept pilot study of a novel technology-based intervention to treat substance use disorders. Am J Drug Alcohol Abuse, 2017. [DOI | PubMed]
130. MJ Freedman, KM Lester, C McNamara, JB Milby, JE Schumacher. Cell phones for ecological momentary assessment with cocaine-addicted homeless patients in treatment. J Subst Abuse Treat, 2006. [DOI | PubMed]
131. BS Linas, C Latkin, A Genz, RP Westergaard, LW Chang, RC Bollinger, GD Kirk. Utilizing mHealth methods to identify patterns of high risk illicit drug use. Drug Alcohol Depend, 2015. [DOI | PubMed]
132. C Yang, B Linas, G Kirk, R Bollinger, L Chang, G Chander, D Siconolfi, S Braxton, A Rudolph, C Latkin. Feasibility and acceptability of smartphone-based ecological momentary assessment of alcohol use among African American men who have sex with men in Baltimore. JMIR Mhealth Uhealth, 2015. [DOI | PubMed]
133. A Buu, LS Massey, MA Walton, JA Cranford, MA Zimmerman, RM Cunningham. Assessment methods and schedules for collecting daily process data on substance use related health behaviors: a randomized control study. Drug Alcohol Depend, 2017. [DOI | PubMed]
134. B Suffoletto, T Chung, F Muench, P Monti, DB Clark. A text message intervention with adaptive goal support to reduce alcohol consumption among non-treatment-seeking young adults: non-randomized clinical trial with voluntary length of enrollment. JMIR Mhealth Uhealth, 2018. [DOI | PubMed]
135. AA Moore, JE Lake, S Glasner, A Karlamangla, A Kuerbis, D Preciado, J Jenkins, BX Dominguez, J Candelario, DH Liao, L Tang, MC Reid. Establishing the feasibility, acceptability and preliminary efficacy of a multi-component behavioral intervention to reduce pain and substance use and improve physical performance in older persons living with HIV. J Subst Abuse Treat, 2019. [DOI | PubMed]
136. S Glasner, H Chokron Garneau, A Ang, L Ray, A Venegas, R Rawson, S Kalichman. Preliminary efficacy of a cognitive behavioral therapy text messaging intervention targeting alcohol use and antiretroviral therapy adherence: a randomized clinical trial. PLoS One, 2020. [DOI | PubMed]
137. SA Spohr, FS Taxman, ST Walters. The relationship between electronic goal reminders and subsequent drug use and treatment initiation in a criminal justice setting. Addict Behav, 2015. [DOI | PubMed]
138. ML Steers, AD Coffman, RE Wickham, JL Bryan, L Caraway, C Neighbors. Evaluation of alcohol-related personalized normative feedback with and without an injunctive message. J Stud Alcohol Drugs, 2016. [DOI | PubMed]
139. JW Ditre, LR LaRowe, PA Vanable, MJ De Vita, MJ Zvolensky. Computer-based personalized feedback intervention for cigarette smoking and prescription analgesic misuse among persons living with HIV (PLWH). Behav Res Ther, 2019. [DOI | PubMed]
140. J Gryczynski, SG Mitchell, RP Schwartz, K Dusek, KE O’Grady, AJ Cowell, C Barbosa, A Barnosky, CC DiClemente. Computer- vs. nurse practitioner-delivered brief intervention for adolescent marijuana, alcohol, and sex risk behaviors in school-based health centers. Drug Alcohol Depend, 2021. [DOI | PubMed]
141. BA Moore, MI Rosen, Y Wang, J Shen, K Ablondi, A Sullivan, M Guerrero, L Siqueiros, ES Daar, H Liu. A remotely-delivered CBT and contingency management therapy for substance using people with HIV. AIDS Behav, 2015. [DOI | PubMed]
142. JC Beckham, KA Adkisson, J Hertzberg, NA Kimbrel, AJ Budney, RS Stephens, SD Moore, PS Calhoun. Mobile contingency management as an adjunctive treatment for co-morbid cannabis use disorder and cigarette smoking. Addict Behav, 2018. [DOI | PubMed]
143. KA Babson, DE Ramo, L Baldini, R Vandrey, MO Bonn-Miller. Mobile app-delivered cognitive behavioral therapy for insomnia: feasibility and initial efficacy among veterans with cannabis use disorders. JMIR Res Protoc, 2015. [DOI | PubMed]
144. VM Mays, AL Jones, A Delany-Brumsey, C Coles, SD Cochran. Perceived discrimination in health care and mental health/substance abuse treatment among Blacks, Latinos, and Whites. Med Care, 2017. [DOI | PubMed]
145. EG Guerrero, JC Marsh, T Khachikian, H Amaro, WA Vega. Disparities in Latino substance use, service use, and treatment: implications for culturally and evidence-based interventions under health care reform. Drug Alcohol Depend, 2013. [DOI | PubMed]
146. DK Espey, MA Jim, N Cobb, M Bartholomew, T Becker, D Haverkamp, M Plescia. Leading causes of death and all-cause mortality in American Indians and Alaska Natives. Am J Public Health, 2014. [DOI | PubMed]
147. S Srinivasan, SD Williams. Transitioning from health disparities to a health equity research agenda: the time is now. Public Health Rep, 2014. [DOI | PubMed]
148. UL McFarling. ‘Health equity tourists’: how white scholars are colonizing research on health disparities. STAT, 2021
149. BE Turner, JR Steinberg, BT Weeks, F Rodriguez, MR Cullen. Race/ethnicity reporting and representation in US clinical trials: a cohort study. Lancet Reg Health Am, 2022. [DOI | PubMed]
150. VL Sanders Thompson, N Ackermann, KL Bauer, DJ Bowen, MS Goodman. Strategies of community engagement in research: definitions and classifications. Transl Behav Med, 2021. [DOI | PubMed]
151. L Sprague Martinez, D Chassler, R Lobb, D Hakim, J Pamphile, TA Battaglia. A discussion among deans on advancing community engaged research. Clin Transl Sci, 2023. [DOI | PubMed]
152. DJ Johnson, MF Brunette, DJ Goodman, M Adams, C Bryer, JR Doherty, V Flanagan, JR Frew, S Mullins, F Sheehan, A Tobar-Santamaria, S Whitney, S Lord. Promoting community stakeholder engagement in research on treatment for pregnant women with opioid use disorder. J Comp Eff Res, 2022. [DOI | PubMed]
153. M Yarborough, K Edwards, P Espinoza, G Geller, A Sarwal, R Sharp, P Spicer. Relationships hold the key to trustworthy and productive translational science: recommendations for expanding community engagement in biomedical research. Clin Transl Sci, 2013. [DOI | PubMed]
154. SM Ahmed, AG Palermo. Community engagement in research: frameworks for education and peer review. Am J Public Health, 2010. [DOI | PubMed]
155. LS Onken, KM Carroll, V Shoham, BN Cuthbert, M Riddle. Reenvisioning clinical science: unifying the discipline to improve the public health. Clin Psychol Sci, 2014. [DOI | PubMed]
156. DP Scharff, KJ Mathews, P Jackson, J Hoffsuemmer, E Martin, D Edwards. More than Tuskegee: understanding mistrust about research participation. J Health Care Poor Underserved, 2010. [DOI | PubMed]
157. CM Pacheco, SM Daley, T Brown, M Filippi, KA Greiner, CM Daley. Moving forward: breaking the cycle of mistrust between American Indians and researchers. Am J Public Health, 2013. [DOI | PubMed]
158. Enhancing health disparities research related to substance use and addiction: research gaps and opportunities. National Institutes of Health (NIH), 2021
159. CC DiClemente, CM Corno, MM Graydon, AE Wiprovnick, DJ Knoblach. Motivational interviewing, enhancement, and brief interventions over the last decade: a review of reviews of efficacy and effectiveness. Psychol Addict Behav, 2017. [DOI | PubMed]
160. DL Goldman. A theory of health disparities and medical technology. Contribut Econ Anal Policy, 2005. [DOI]
161. C Senteio, T Veinot. Trying to make things right: adherence work in high-poverty, African American neighborhoods. Qual Health Res, 2014. [DOI | PubMed]
162. CE Brown, JR Curtis, KM Doll. A race-conscious approach toward research on racial inequities in palliative care. J Pain Symptom Manage, 2022. [DOI | PubMed]
163. LC Brewer, KL Fortuna, C Jones, R Walker, SN Hayes, CA Patten, LA Cooper. Back to the future: achieving health equity through health informatics and digital health. JMIR Mhealth Uhealth, 2020. [DOI | PubMed]
164. GG Ramos, AE West, C Begay, VM Telles, J D’Isabella, V Antony, C Soto. Substance use disorder and homelessness among American Indians and Alaska Natives in California. J Ethn Subst Abuse, 2023. [DOI | PubMed]
165. PM Roman, LJ Ducharme, HK Knudsen. Patterns of organization and management in private and public substance abuse treatment programs. J Subst Abuse Treat, 2006. [DOI | PubMed]
166. AM Cislo, R Trestman. Challenges and solutions for conducting research in correctional settings: the U.S. experience. Int J Law Psychiatry, 2013. [DOI | PubMed]
167. WJ Ferguson, D Cloud, AC Spaulding, D Shelton, RL Trestman, FL Altice, C Champion-Lippmann, D Thomas, FS Taxman. A call to action: a blueprint for academic health sciences in the era of mass incarceration. J Health Care Poor Underserved, 2016. [DOI | PubMed]
168. 2014. The Trends in Indian health: 2014 Edition, 2015
169. Rural America at a glance, 2021 edition. Economic Research Service, US Department of Agriculture
170. K Burlew, S Larios, L Suarez-Morales, B Holmes, K Venner, R Chavez. Increasing ethnic minority participation in substance abuse clinical trials: lessons learned in the National Institute on Drug Abuse’s Clinical Trials Network. Cultur Divers Ethnic Minor Psychol, 2011. [DOI | PubMed]
171. IC Sankaré, R Bross, AF Brown, HE Del Pino, LF Jones, DM Morris, C Porter, A Lucas-Wright, R Vargas, N Forge, KC Norris, KL Kahn. Strategies to build trust and recruit African American and Latino community residents for health research: a cohort study. Clin Transl Sci, 2015. [DOI | PubMed]
172. LT Das, E Kutscher. Stimulant use disorders in the United States- is another epidemic on the horizon?. JAMA Health Forum, 2020. [DOI | PubMed]
173. 173National Academies of Sciences, Engineering, and MedicineHealth and Medicine DivisionBoard on Population Health and Public Health PracticeThe Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research2017Washington, DCNational Academies Press
174. MM Sweeney, AF Holtyn, ML Stitzer, DR Gastfriend. Practical technology for expanding and improving substance use disorder treatment: telehealth, remote monitoring, and digital health interventions. Psychiatr Clin North Am, 2022. [DOI | PubMed]
175. EC Williams, JH Samet. Shifts at the Helm: gratitude, re-commitment to our work, and a call for addictions disparities research. Addict Sci Clin Pract, 2022. [DOI | PubMed]
176. BJ Biroscak, MV Pantalon, JD Dziura, DP Hersey, FE Vaca. Use of non-face-to-face modalities for emergency department screening, brief intervention, and referral to treatment (ED-SBIRT) for high-risk alcohol use: a scoping review. Subst Abus, 2019. [DOI | PubMed]
177. S Colbert, L Thornton, R Richmond. Smartphone apps for managing alcohol consumption: a literature review. Addict Sci Clin Pract, 2020. [DOI | PubMed]
178. R Colonna, L Alvarez. Characteristics of mobile-based brief interventions targeting substance use among youth: a rapid review. J Subst Use, 2022. [DOI]
179. D Crane, C Garnett, J Brown, R West, S Michie. Behavior change techniques in popular alcohol reduction apps: content analysis. J Med Internet Res, 2015. [DOI | PubMed]
180. RA McGinnes, JE Hutton, TJ Weiland, DM Fatovich, D Egerton-Warburton. Review article: effectiveness of ultra-brief interventions in the emergency department to reduce alcohol consumption: a systematic review. Emerg Med Australas, 2016. [DOI | PubMed]
181. B Tofighi, C Chemi, J Ruiz-Valcarcel, P Hein, L Hu. Smartphone apps targeting alcohol and illicit substance use: systematic search in in commercial app stores and critical content analysis. JMIR Mhealth Uhealth, 2019. [DOI | PubMed]
182. H Wilson, SR Stoyanov, S Gandabhai, A Baldwin. The quality and accuracy of mobile apps to prevent driving after drinking alcohol. JMIR Mhealth Uhealth, 2016. [DOI | PubMed]
183. R Colonna, P Tucker, J Holmes, J Wilson, L Alvarez. Mobile-based brief interventions targeting cannabis-impaired driving among youth: a Delphi study. J Subst Abuse Treat, 2022. [DOI | PubMed]
184. D Furr-Holden, AJ Milam, L Wang, R Sadler. African Americans now outpace whites in opioid-involved overdose deaths: a comparison of temporal trends from 1999 to 2018. Addiction, 2021. [DOI | PubMed]
185. ML Barnett, E Meara, T Lewinson, B Hardy, D Chyn, M Onsando, HA Huskamp, A Mehrotra, NE Morden. Racial inequality in receipt of medications for opioid use disorder. N Engl J Med, 2023. [DOI | PubMed]
186. T Iheanacho, K Payne, J Tsai. Mobile, community-based buprenorphine treatment for veterans experiencing homelessness with opioid use disorder: a pilot, feasibility study. Am J Addict, 2020. [DOI | PubMed]
187. TC Saraiya, M Swarbrick, L Franklin, S Kass, AN Campbell, DA Hien. Perspectives on trauma and the design of a technology-based trauma-informed intervention for women receiving medications for addiction treatment in community-based settings. J Subst Abuse Treat, 2020. [DOI | PubMed]
188. AF Holtyn, F Toegel, MD Novak, JM Leoutsakos, M Fingerhood, K Silverman. Remotely delivered incentives to promote buprenorphine treatment engagement in out-of-treatment adults with opioid use disorder. Drug Alcohol Depend, 2021. [DOI | PubMed]
189. MJ Lynch, P Houck, J Meyers, J Schuster, DM Yealy. Use of a telemedicine bridge clinic to engage patients in opioid use disorder treatment. J Addict Med, 2022. [DOI | PubMed]
190. Second temporary extension of COVID-19 telemedicine flexibilities for prescription of controlled medications. Federal Register, 2023
191. CL Ford, CO Airhihenbuwa. The public health critical race methodology: praxis for antiracism research. Soc Sci Med, 2010. [DOI | PubMed]
192. HD Dean, KM Williams, KA Fenton. From theory to action: applying social determinants of health to public health practice. Public Health Rep, 2013. [DOI]
193. RM Ryan, EL Deci. Self-determination theory and the facilitation of intrinsic motivation, social development, and well-being. Am Psychol, 2000. [DOI | PubMed]
194. H Patrick, GC Williams. Self-determination theory: its application to health behavior and complementarity with motivational interviewing. Int J Behav Nutr Phys Act, 2012. [DOI | PubMed]
195. D Hamideh, C Nebeker. The digital health landscape in addiction and substance use research: will digital health exacerbate or mitigate health inequities in vulnerable populations?. Curr Addict Rep, 2020. [DOI]
196. A Weaver, JA Himle, RJ Taylor, NN Matusko, JM Abelson. Urban vs rural residence and the prevalence of depression and mood disorder among African American women and non-Hispanic White women. JAMA Psychiatry, 2015. [DOI | PubMed]
197. RA Harris, DS Mandell. Years of life lost to drug overdose among Black female individuals in the US, 2015-2021. JAMA Psychiatry, 2023. [DOI | PubMed]
198. E Heard, L Fitzgerald, B Wigginton, A Mutch. Applying intersectionality theory in health promotion research and practice. Health Promot Int, 2020. [DOI | PubMed]
199. L Husain, T Greenhalgh, G Hughes, T Finlay, J Wherton. Desperately seeking intersectionality in digital health disparity research: narrative review to inform a richer theorization of multiple disadvantage. J Med Internet Res, 2022. [DOI | PubMed]
200. K Crenshaw. Mapping the margins: intersectionality, identity politics, and violence against women of color. Stan Law Rev, 1991. [DOI]
201. L Tinner, D Holman, S Ejegi-Memeh, AA Laverty. Use of intersectionality theory in interventional health research in high-income countries: a scoping review. Int J Environ Res Public Health, 2023. [DOI | PubMed]
202. Science of behavior change. National Institues of Health OoSC-TCF, 2023
203. Nora’s blog: social determinants of health can’t be extricated from addiction science. National Institute on Drug Abuse
204. E Lett, D Adekunle, P McMurray, EN Asabor, W Irie, MA Simon, R Hardeman, MR McLemore. Health equity tourism: ravaging the justice landscape. J Med Syst, 2022. [DOI | PubMed]
205. D Tod, A Booth, B Smith. Critical appraisal. Int Rev Sport Exerc Psychol, 2021. [DOI]
206. J O’Neill, H Tabish, V Welch, M Petticrew, K Pottie, M Clarke, T Evans, J Pardo Pardo, E Waters, H White, P Tugwell. Applying an equity lens to interventions: using PROGRESS ensures consideration of socially stratifying factors to illuminate inequities in health. J Clin Epidemiol, 2014. [DOI | PubMed]
207. H McGhee. The Sum of Us: What Racism Costs Everyone and How We Can Prosper Together, 2021
208. R Benjamin. Race After Technology: Abolitionist Tools for the New Jim Code, 2019